Case Study

Tau Pathology Clinical Trial


The IMP under study in this trial was a monoclonal antibody that has been shown in preclinical studies to suppress cerebrospinal fluid concentrations of extracellular tau (eTau). eTau has been implicated in the spreading of tau pathology as it disrupts synaptic activity in vitro and hence is presumed to have a similar effect in vivo.

However, working with monoclonal antibodies as therapeutics presents many challenges. For example, the IMP in this trial is only stable for 24 hours after preparation. Even minor delays and disruptions in delivery of the IMP to patients can compromise its quality, and this is exacerbated when the treatment needs to be shipped across different time zones from a central pharmacy, as was the case in the USA. Moreover, scheduling appointments – never mind keeping them – becomes a logistical challenge for all involved when different time zones need to be factored in.

To find out how these challenges were addressed, download the available case study.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader

MRN - Medical Research Network